Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
Abbott LaboratoriesABT |
$1.05B |
 |
Tempus AITEM |
-$125B |
 |
SolventumSOLV |
-$1.88B |
 |
TeleflexTFX |
$5.2M |
 |
Universal Health ServicesUHS |
-$32M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| FENNELL GEORGE | Feb 10, 2026 | Sell | 2,809 | $649.2599 | $1.8M |
| FENNELL GEORGE | Feb 10, 2026 | Sell | 2,782 | $646.2259 | $1.8M |
| FENNELL GEORGE | Feb 10, 2026 | Sell | 2,161 | $645.2512 | $1.4M |
| FENNELL GEORGE | Feb 10, 2026 | Sell | 1,130 | $642.9974 | $730,000 |
| FENNELL GEORGE | Feb 10, 2026 | Sell | 1,060 | $647.2066 | $690,000 |
| FENNELL GEORGE | Feb 10, 2026 | Sell | 966 | $648.7792 | $630,000 |
| FENNELL GEORGE | Feb 10, 2026 | Sell | 397 | $644.016 | $260,000 |
| FENNELL GEORGE | Feb 10, 2026 | Sell | 40 | $650.32 | $26,000 |
| Hunt Nimrata | Nov 7, 2025 | Sell | 5,114 | $702.2017 | $3.6M |
| Hunt Nimrata | Nov 7, 2025 | Sell | 1,468 | $704.8659 | $1M |
| Hunt Nimrata | Nov 7, 2025 | Sell | 1,465 | $703.7339 | $1M |
| Hunt Nimrata | Nov 7, 2025 | Sell | 1,378 | $705.5448 | $970,000 |
| SZOSTAK M ANNE | Aug 22, 2025 | Sell | 2,187 | $647.3252 | $1.4M |
| Erickson Michael G | Aug 12, 2025 | Sell | 318 | $649.99 | $210,000 |
| Erickson Michael G | Aug 12, 2025 | Sell | 88 | $649.8507 | $57,000 |
| Hunt Nimrata | Aug 11, 2025 | Sell | 1,200 | $656.5335 | $790,000 |
| Underberg Sharon E. | Aug 8, 2025 | Sell | 5,450 | $651.6 | $3.6M |
| Hunt Nimrata | Aug 6, 2025 | Sell | 3,018 | $629.865 | $1.9M |
| Hunt Nimrata | Aug 6, 2025 | Sell | 2,907 | $630.9087 | $1.8M |
| Hunt Nimrata | Aug 6, 2025 | Sell | 1,218 | $630.6891 | $770,000 |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 7,299 | $631.6065 | $4.6M |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 6,056 | $630.5935 | $3.8M |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 3,526 | $635.1268 | $2.2M |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 3,397 | $629.8228 | $2.1M |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 3,000 | $632.563 | $1.9M |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 1,822 | $636.1517 | $1.2M |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 1,525 | $628.272 | $960,000 |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 1,095 | $626.9024 | $690,000 |
| Lane Michael | Aug 6, 2025 | Sell | 5,631 | $627.5634 | $3.5M |
| Lane Michael | Aug 6, 2025 | Sell | 2,480 | $627.9911 | $1.6M |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 880 | $636.8083 | $560,000 |
| MAZELSKY JONATHAN JAY | Aug 6, 2025 | Sell | 660 | $639.3718 | $420,000 |
| Lane Michael | Aug 6, 2025 | Sell | 300 | $628.8866 | $190,000 |
| SZOSTAK M ANNE | May 21, 2025 | Sell | 1,260 | $512.3371 | $650,000 |
| SZOSTAK M ANNE | May 21, 2025 | Sell | 1,046 | $513.74 | $540,000 |
| JUNIUS DANIEL M | May 13, 2025 | Sell | 2,683 | $506.4097 | $1.4M |
| Vandebroek Sophie V. | May 9, 2025 | Sell | 1,279 | $491.3411 | $630,000 |
| FENNELL GEORGE | Feb 10, 2025 | Sell | 9,986 | $462.5337 | $4.6M |
| SZOSTAK M ANNE | Feb 7, 2025 | Sell | 3,000 | $465.945 | $1.4M |
| Vandebroek Sophie V. | Nov 27, 2024 | Sell | 344 | $420.435 | $140,000 |
| SZOSTAK M ANNE | Sep 6, 2024 | Sell | 500 | $469.3723 | $230,000 |
| Claflin Bruce L. | May 17, 2024 | Sell | 200 | $540.8 | $110,000 |
| POLEWACZYK JAMES F | Mar 6, 2024 | Sell | 4,134 | $557.941 | $2.3M |
| POLEWACZYK JAMES F | Mar 6, 2024 | Sell | 3,290 | $558.8822 | $1.8M |
| POLEWACZYK JAMES F | Mar 6, 2024 | Sell | 680 | $559.3318 | $380,000 |
| Vandebroek Sophie V. | Mar 5, 2024 | Sell | 1,404 | $562.9822 | $790,000 |
FAQ - Insider Transactions
The most recent insider transaction for Idexx Laboratories was conducted by FENNELL GEORGE, who sold 2,809 shares on February 10, 2026 at a price of $649.26 per share.
MAZELSKY JONATHAN JAY has sold the most IDXX stock in the last 2 years, with a total value of $18M.
The total value of insider transactions for Idexx Laboratories in the last 2 years is negative, amounting to -$63M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Idexx Laboratories have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
